Articles tagged with: CUDC-907
News»

Good morning, myeloma world.
It's just Tuesday, and already the week is getting interesting. We'll be reporting on just two myeloma-related news items today, but one of them is the kind of news we don't see here at Myeloma Morning very often.
In particular, the German biotech company MorphoSys has sued Janssen Biotech and Genmab, the two companies that have developed and marketed Darzalex (daratumumab). MorphoSys contends that sales of Darzalex infringe on a MorphoSys patent.
In addition, we report on a study that came out last …
News»

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a number of poster presentations related to multiple myeloma.
During “poster sessions” at conferences such as the ASCO meeting, research results are made available for review by meeting attendees in the form of posters, each of which summarizes the results of a single study. Each poster is typically about two feet high by three or four feet in length, and all posters during a session are displayed throughout a large conference hall.
Most of the myeloma-related …
News»

At this year’s American Society of Hematology (ASH) meeting, which will be held in early December, more than 100 oral presentations and about 400 poster presentations will summarize research focused on multiple myeloma.
Abstracts for these presentations are now available.
During the next several weeks, The Beacon will publish a series of articles previewing the myeloma-related studies from the ASH meeting that are of particular interest.
Each of the articles will cover abstracts related to a specific topic, such as new treatments under development, current treatments, stem cell transplantation, prognostic factors, and …
NewsFlash »
GDC-0941 May Be Active In Multiple Myeloma – Results of a recent preclinical study suggest that the investigational drug GDC-0941, which is being developed by the biotech company Genentech, may have anti-myeloma activity and may increase the activity of Revlimid (lenalidomide) and dexamethasone (Decadron). Like perifosine, another investigational myeloma treatment, GDC-0941 inhibits an enzyme in cancer cells known as phosphoinositide 3-kinase (PI3K). By inhibiting PI3K, GDC-0941 disrupts the cell division cycle and causes cancer cell death. It is being investigated as a treatment for a variety of different cancers, including breast cancer and lung cancer. Based on their findings, the researchers recommend that GDC-0941 be further developed as a potential treatment for myeloma. For more information, please see the study in the journal Oncogene (abstract).
Phase 1 Clinical Trial To Study CUDC-907 In Multiple Myeloma And Lymphoma Patients – The pharmaceutical company Curis (NASDAQ:CRIS) has launched a Phase 1 trial of CUDC-907 in patients with relapsed and refractory multiple myeloma or lymphoma. Patients must have received at least two prior therapies to be eligible for the study. CUDC-907 is a multi-targeted agent that inhibits both PI3K and histone deacetylase (HDAC) in cancer cells. Other HDAC inhibitors that are being investigated as potential treatments for multiple myeloma include Zolinza (vorinostat), panobinostat, and ricolinostat (ACY-1215). For more information, including trial locations, please see the clinical trial description.
LLS Teleconference About Latest Myeloma Research From ASH – On January 29, the Leukemia & Lymphoma Society (LLS) will sponsor a free teleconference call about the latest myeloma research from the American Society of Hematology (ASH) annual meeting. Dr. Kenneth Anderson, director of the Jerome Lipper Myeloma Center at the Dana-Farber Cancer Institute in Boston, will lead the program, which will run from noon till 1:30 p.m. Eastern Time. Dr. Anderson will speak about current and emerging myeloma treatments, the role of clinical trials in the development of myeloma treatment, and advances in the management of treatment side effects. For more information or to register, please see the LLS website.